Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Treatment with acalabrutinib in IGHV mutated setting and presence of splenomegaly are the main predictors of faster lymphocyte count decrease in CLL during monotherapy with cbtki

Blood (2025) 146 (Supplement 1): 7427.

https://doi.org/10.1182/blood-2025-7427

Published: 2025

Journal Articles

Btkis and DRC show a reduction of infections and need of hospitalization towards BR and other chemo-immunotherapies in waldenstrom macroglobulinemia.

Blood (2025) 146 (Supplement 1): 1833.

https://doi.org/10.1182/blood-2025-1833

Published: 2025

Journal Articles

Very low risk for secondary malignancies with btkis in Waldenström macroglobulinemia: A retrospective real-world multicenter study.

Blood (2025) 146 (Supplement 1): 5390.

https://doi.org/10.1182/blood-2025-5390

Published: 2025

Journal Articles

Oncogeriatric assessment of patients with chronic lymphatic leukaemia over 65 years old undergoing target therapies: A pilot study conducted at the fondazione policlinico gemelli.

Idanna Innocenti, Giuseppe Ferdinando Colloca, Luca Stirparo, Annamaria Tomasso, Tommaso Quaranta, Antonio Mosca, Francesco Iadevaia, Feliciana Guglielmi, Andrea Bellieni, Francesco Landi, Giulia Giordano, Francesco Autore, Alberto Fresa, Dimitar Efremov, Luca Laurenti

Blood (2025) 146 (Supplement 1): 7412.

https://doi.org/10.1182/blood-2025-7412

Published: 2025

Journal Articles

Longitudinal analysis of richter syndrome risk and survival in CLL: The role of targeted therapy and molecular markers. experience at the fondazione policlinico gemelli in rome.

Idanna Innocenti, Tommaso Quaranta, Francesco Iadevaia, Annamaria Tomasso, Luca Stirparo, Antonio Mosca, Alberto Fresa, Giulia Benintende, Florenzia Vuono, Feliciana Guglielmi, Pier Luigi Abbate, Arianna Bakacs, Dimitar Efremov, Eugenio Sangiorgi, Francesco Autore, Luca Laurenti

Blood (2025) 146 (Supplement 1): 5679.

https://doi.org/10.1182/blood-2025-5679

Published: 2025

Journal Articles

Chronic obstructive pulmonary disease and prior pneumonia as predictors of infectious risk in chronic lymphocytic leukemia patients receiving acalabrutinib or zanubrutinib: A seifem multicentre Study.

Blood (2025) 146 (Supplement 1): 5678.

https://doi.org/10.1182/blood-2025-5678

Published: 2025

Journal Articles

Absence of lymphocytosis after starting treatment with cbtki is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.

Blood (2025) 146 (Supplement 1): 5671.

https://doi.org/10.1182/blood-2025-5671

Published: 2025

Journal Articles

Acalabrutinib in High-Risk Chronic Lymphocytic Leukemia Patients Naïve or Previous Treated. a Multicenter Retrospective Observational Real-Life Experience

Blood (2024) 144 (Supplement 1): 6798.

https://doi.org/10.1182/blood-2024-203557

Published: 2024

Journal Articles

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Enrica Antonia Martino, Raffaella Pasquale, Isacco Ferrarini, Riccardo Moia, Andrea Visentin, Alessandro Sanna, Marina Motta, Massimo Moratti, Paolo Sportoletti, Annalisa Chiarenza, Alessandro Maggi, Valentina Zammit, Michele Merli, Idanna Innocenti, Claudia Giordano, Laura Nocilli, Massimiliano Postorino, Caterina Stelitano, Andrea Ferrario, Annamaria Frustaci, Stefania Scardino, Paola Anticoli Borza, Laura Ballotta, Salvatrice Mancuso, Gerardo Musuraca, Anna Mele, Sara Galimberti, Gioacchino Catania, Annamaria Giordano, Ilaria Angeletti, Luana Schiattone, Elsa Pennese, Rosanna Miccolis, Angelo Fama, Giulio Giordano, Catello Califano, Ernesto Vigna, Antonella Bruzzese, Giuliana Farina, Pietro Bulian, Giacomo Loseto, Barbara Pocali, Vanessa Innao, Piero Galieni, Vincenzo Ludovico Fraticelli, Candida Vitale, Azzurra Anna Romeo, Marco Rossi, Ilaria Scortechini, Federico Vozzella, Luigi Malandruccolo, Enrico Derenzini, Valentina di Martina, Roberto Marasca, Maria Ilaria Del Principe, Marta Coscia, Nicola Di Renzo, Luca Laurenti, Antonino Neri, Pellegrino Musto, Francesco Di Raimondo, Alessandra Tedeschi, Livio Trentin, Gianluca Gaidano, Fortunato Morabito, Valter Gattei, Massimo Gentile

Blood (2024) 144 (Supplement 1): 6794.

https://doi.org/10.1182/blood-2024-205354

Published: 2024

Journal Articles

Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre Study

Blood (2024) 144 (Supplement 1): 3013.

https://doi.org/10.1182/blood-2024-200111

Published: 2024

Journal Articles

Incidence of Atrial Fibrillation (AF) in Chronic Lymphocytic Leukemia (CLL) Patients: A Real-World Retrospective Comparison of Ibrutinib and Acalabrutinib

Roberta Murru, Idanna Innocenti, Andrea Galitzia, Annamaria Tomasso, Caterina Chessa, Marco Murineddu, Alberto Fresa, Valeria Oggianu, Francesco Autore, Antonio Mosca, Giovanni Caocci, Angelo D. Palmas, Giorgio La Nasa, Luca Laurenti

Blood (2024) 144 (Supplement 1): 6779.

https://doi.org/10.1182/blood-2024-208899

Published: 2024

Journal Articles

Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study

Blood (2024) 144 (Supplement 1): 4621.

https://doi.org/10.1182/blood-2024-205215

Published: 2024

Journal Articles

Prevention of CINV in Patients with Multiple Myeloma or Lymphoma Undergoing Hematopoietic Stem Cell Transplantation: NEPA Versus Ondansetron. a Monocentric Real-Life Experience

Blood (2023) 142 (Supplement 1): 7067.

https://doi.org/10.1182/blood-2023-187545

Published: 2023

Journal Articles

Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study

Blood (2023) 142 (Supplement 1): 6529.

https://doi.org/10.1182/blood-2023-181037

Published: 2023

Journal Articles

Impact of COVID-19 in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Possible Role of the Association to Anti-CD20 Antibody? a Multicentre Seifem Study

Blood (2023) 142 (Supplement 1): 3283.

https://doi.org/10.1182/blood-2023-180955

Published: 2023

Journal Articles

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Blood (2023) 142 (Supplement 1): 3281.

https://doi.org/10.1182/blood-2023-174897

Published: 2023

Journal Articles

Kinetics of Lymphocytosis during First-Line Treatment with BTK Covalent Inhibitors in Chronic Lymphocytic Leukemia Patients: An Italian Multicenter Experience of Real Life

Blood (2023) 142 (Supplement 1): 6545.

https://doi.org/10.1182/blood-2023-188941

Published: 2023

Journal Articles

Real-Life Multicentre Study on 547 Patients Affected By Waldenstrom Macroglobulinemia Treated with Chemo-Immunotherapy: Which Is the Best and Most Used First-Line Treatment?

Blood (2023) 142 (Supplement 1): 1667.

https://doi.org/10.1182/blood-2023-179460

Published: 2023

Journal Articles

VEGF and IL-6 As Markers of Severity and Response to Treatment in Waldenstrom Macroglobulinemia and IgM-Monoclonal Gammopathy of Undetermined Significance: A Monocentric Experience

Annamaria Tomasso, Idanna Innocenti, Giulia Benintende, Francesco Autore, Alberto Fresa, Florenzia Vuono, Luca Stirparo, Antonio Mosca, Claudia Giannotta, Dimitar G Efremov, Marco Luigetti, Silvia Baroni, Luca Laurenti

Blood (2022) 140 (Supplement 1): 12498–12500.

https://doi.org/10.1182/blood-2022-165487

Published: 2022

Journal Articles

Predictive and Prognostic Molecular Biomarkers in Familial Chronic Lymphocytic Leukemia: A Pilot Monocentric Study

Giulia Benintende, Idanna Innocenti, Alberto Fresa, Francesco Autore, Annamaria Tomasso, Florenzia Vuono, Luca Stirparo, Antonio Mosca, Dimitar G Efremov, Andrea Bacigalupo, Luca Laurenti

Blood (2022) 140 (Supplement 1): 7018–7019.

https://doi.org/10.1182/blood-2022-169897

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Treatment with acalabrutinib in IGHV mutated setting and presence of splenomegaly are the main predictors of faster lymphocyte count decrease in CLL during monotherapy with cbtki

Btkis and DRC show a reduction of infections and need of hospitalization towards BR and other chemo-immunotherapies in waldenstrom macroglobulinemia.

Very low risk for secondary malignancies with btkis in Waldenström macroglobulinemia: A retrospective real-world multicenter study.

Oncogeriatric assessment of patients with chronic lymphatic leukaemia over 65 years old undergoing target therapies: A pilot study conducted at the fondazione policlinico gemelli.

Longitudinal analysis of richter syndrome risk and survival in CLL: The role of targeted therapy and molecular markers. experience at the fondazione policlinico gemelli in rome.

Chronic obstructive pulmonary disease and prior pneumonia as predictors of infectious risk in chronic lymphocytic leukemia patients receiving acalabrutinib or zanubrutinib: A seifem multicentre Study.

Absence of lymphocytosis after starting treatment with cbtki is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.

Acalabrutinib in High-Risk Chronic Lymphocytic Leukemia Patients Naïve or Previous Treated. a Multicenter Retrospective Observational Real-Life Experience

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre Study

Incidence of Atrial Fibrillation (AF) in Chronic Lymphocytic Leukemia (CLL) Patients: A Real-World Retrospective Comparison of Ibrutinib and Acalabrutinib

Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study

Prevention of CINV in Patients with Multiple Myeloma or Lymphoma Undergoing Hematopoietic Stem Cell Transplantation: NEPA Versus Ondansetron. a Monocentric Real-Life Experience

Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study

Impact of COVID-19 in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Possible Role of the Association to Anti-CD20 Antibody? a Multicentre Seifem Study

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Kinetics of Lymphocytosis during First-Line Treatment with BTK Covalent Inhibitors in Chronic Lymphocytic Leukemia Patients: An Italian Multicenter Experience of Real Life

Real-Life Multicentre Study on 547 Patients Affected By Waldenstrom Macroglobulinemia Treated with Chemo-Immunotherapy: Which Is the Best and Most Used First-Line Treatment?

VEGF and IL-6 As Markers of Severity and Response to Treatment in Waldenstrom Macroglobulinemia and IgM-Monoclonal Gammopathy of Undetermined Significance: A Monocentric Experience

Predictive and Prognostic Molecular Biomarkers in Familial Chronic Lymphocytic Leukemia: A Pilot Monocentric Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only